matter-of-fact

SP Kalantri

You are reading

Covid: In search of a new oral antiviral

Skip to Content

matter-of-fact

SP Kalantri

matter-of-fact

SP Kalantri

Home Covid Covid: In search of a new oral antiviral
Covid

Covid: In search of a new oral antiviral

by SP Kalantri29 December 202229 December 2022Leave a Comment on Covid: In search of a new oral antiviral

Search for an oral antiviral that can prevent disease progression and hasten recovery in Covid is on.

Today’s @NEJM reports a clinical trial from China that tested a previously unknown oral drug in symptomatic outpatients with #COVID19. n/1

— SP Kalantri (@spkalantri) December 29, 2022

Because access to nirmatrelvir is limited worldwide, the authors wondered if VV116, an oral antiviral, hasten clinical recovery, resolve symptoms, and prevent disease progression as effectively and as safely as Nirmatrelvir-Ritonavir? n/3

— SP Kalantri (@spkalantri) December 29, 2022

Study participants—symptomatic participants infected with omicron subvariants at high risk for progression to severe Covid-19—came from 7 hospitals in Shanghai, China between April 4, 2022, and May 2, 2022. n/4

— SP Kalantri (@spkalantri) December 29, 2022

They were randomly assigned in a 1:1 ratio to receive either oral VV116 or oral nirmatrelvir–ritonavir for 5 days. n/5

— SP Kalantri (@spkalantri) December 29, 2022

The median age was 53 years and half were women. Most participants had mild Covid-19, and 75% were fully vaccinated or boosted. A third had heart disease or were obese. Most participants received trial regimens within 5 days after symptom onset. n/6

— SP Kalantri (@spkalantri) December 29, 2022

What did the authors find? First, sustained clinical recovery occurred in 377 participants in the VV116 group and 378 participants in the nirmatrelvir–ritonavir group. n/7

— SP Kalantri (@spkalantri) December 29, 2022

Second, the estimated median time to sustained clinical recovery was almost similar—4 days and 5 days, respectively. n/8

— SP Kalantri (@spkalantri) December 29, 2022

Third, no participants in this trial had died or had had progression to severe Covid-19. The median time from randomization to a first negative SARS-CoV-2 test was 7 days in both groups. n/9

— SP Kalantri (@spkalantri) December 29, 2022

Fourth, participants who received VV116 reported fewer adverse events than those who received nirmatrelvir–ritonavir (67.4% vs. 77.3%). n/10

— SP Kalantri (@spkalantri) December 29, 2022

Now that VV116 has shown that it works and is safe, could it replace Nirmatrelvir-Ritonavir for prevention of disease progression in #COVID19 infected outpatients? Only time will tell. n/11 END

— SP Kalantri (@spkalantri) December 29, 2022

Post Navigation

Previous ArticleMolnupiravir fails. When the baseline risk is so low, don’t expect the drug to work.
Next ArticleDr. Anant Ranade

Recent Posts

  • The Dark Room
  • Happy Birthday, Pendsey!
  • Doing away with MD thesis
  • The Double-Blind MD Thesis
  • The fall of the MD thesis

Archives

Categories

Recommended Articles

Covid

Covid and Community Transmission

22 September 20206 November 2022
Covid

Politics of Science in a Pandemic

12 December 20205 November 2022
Covid

Is Remdesivir a Rambaan remedy for Covid?

19 April 20218 November 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

  • MGIMSSevagram

    𝗠𝗚𝗜𝗠𝗦 𝟭𝟵𝟴𝟯: 𝗧𝗲𝗮𝗰𝗵𝗶𝗻𝗴 𝗔𝗴𝗮𝗶𝗻𝘀𝘁 𝘁𝗵𝗲 𝗖𝗹𝗼𝗰𝗸

    18 June 2024
  • MGIMSSevagram

    𝗠𝗲𝗻𝘁𝗼𝗿𝘀, 𝗠𝗲𝗺𝗼𝗿𝗶𝗲𝘀, 𝗮𝗻𝗱 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲: 𝗠𝘆 𝗝𝗼𝘂𝗿𝗻𝗲𝘆 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗠𝗚𝗜𝗠𝗦

    15 June 2024
  • MGIMSSevagram

    Stepping Down…

    21 January 2023
  • MGIMSSevagram

    𝗙𝗮𝗿𝗲𝘄𝗲𝗹𝗹 𝘁𝗼 𝗮 𝗟𝗲𝗴𝗲𝗻𝗱: 𝗛𝗼𝗻𝗼𝗿𝗶𝗻𝗴 𝗗𝗿. 𝗢𝗣 𝗚𝘂𝗽𝘁𝗮’𝘀 𝗥𝗲𝘁𝗶𝗿𝗲𝗺𝗲𝗻𝘁 𝗳𝗿𝗼𝗺 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲

    1 August 2023

Recent Comments

  • Tejal on Happy Birthday, Pendsey!
  • uday mahorkar on A Tribute to Sudhakar Joshi
  • dr. mrs. R S Suryawanshi on A Tribute to Sudhakar Joshi
  • Dr.Ramesh Karwa on Remembering Dr. H.C. Attal
  • Dr Vivek Kirpekar on Remembering Dr. H.C. Attal

Tags

Boy's hostel Breast Cancer Cancer CAT Scan Clinical trials Cobra Covid Doctors Dr. Sushila Nayar Drug Industry Drugs EBM education Ethics GMC Nagpur Hospital India krait MD Medical College Medical Education Medical Students Medicine MGIMS mortality Nagpur ODI Palliative Care Patients Physician postgraduation RCT research Researcher Reunion Rural India Science Sevagram Sponsor Sushila Nayar Teacher Therapy thesis venomous snakes World Cup
2022 © SP Kalantri